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A B S T R A C T
Because of increasing antimicrobial resistance and the shortage of new antibiotics, there is a growing need to
optimize the use of old and new antibiotics. Modelling of the pharmacokinetic/pharmacodynamic (PK/PD)
characteristics of antibiotics can support the optimization of dosing regimens. Antimicrobial eﬃcacy is de-
termined by susceptibility of the drug to the microorganism and exposure to the drug, which relies on the PK and
the dose. Population PK models describe relationships between patients characteristics and drug exposure. This
article highlights three clinical applications of these models applied to antibiotics: 1) dosing evaluation of old
antibiotics, 2) setting clinical breakpoints and 3) dosing individualization using therapeutic drug monitoring
(TDM). For each clinical application, challenges regarding interpretation are discussed. An important challenge
is to improve the understanding of the interpretation of modelling results for good implementation of the dosing
recommendations, clinical breakpoints and TDM advices. Therefore, also background information on PK/PD
principles and approaches to analyse PK/PD data are provided.
1. Introduction
Increasing antimicrobial resistance and the shortage of new anti-
biotics have emphasized the importance of optimizing dosing regimens
of old and new antibiotics in order to improve clinical outcomes of
infections [1]. Modelling of the pharmacokinetic and pharmacody-
namic (PK/PD) characteristics of antibiotics can support the optimiza-
tion of dosing regimens. PK/PD of antibiotics describe the relationship
between eﬃcacy, the in vitro susceptibility of a drug to the micro-
organism (usually expressed as MIC, minimal inhibitory concentration)
and the in vivo exposure to the drug, which relies on the PK and the dose
(Fig. 1) [1]. From this relationship follows that if the MIC is known, the
microbiological and clinical outcome of treatment is determined by the
individual PK proﬁle and dose. To predict that exposure, population PK
models can and are being used. The quality of the model used will
determine the value of the estimated exposure.
During new drug development, population PK models of antibiotics
are recommended to use for optimizing dosing regimens [2]. Popula-
tion PK models are also used to improve dosing regimens of old anti-
biotics in current use and to individualize treatment in the clinical
setting. Many currently used antibiotics were developed and approved
decades ago when PK/PD principles were largely unknown and so-
phisticated population PK modelling techniques did not exist [3].
Nowadays, some of these old antibiotics are studied again and an in-
creasing number of population PK models are published with new
dosing recommendations for speciﬁc populations.
Suﬃcient understanding of the interpretation of modelling results is
essential for good implementation of these dosing recommendations.
Therefore, this article provides background information on the PK/PD
principles of antibiotics (Section 2) and the diﬀerent approaches of
analyzing PK/PD data (Section 3) with the objective to understand the
published population PK models and their clinical applications. Section
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T
4 discusses the clinical applications of population PK models of anti-
biotics (dosing evaluation of old antibiotics, setting clinical MIC
breakpoints and therapeutic drug monitoring) including challenges
regarding the interpretation of modelling results.
2. PK/PD principles of antibiotics
2.1. PK/PD indices
PK/PD indices describe exposure-response relationships. A PK/PD
index represents the relationship between a PK measure of exposure to
the antibacterial agents (such as AUC, area under the concentration-
time curve, or Cmax, maximal concentration) and a PD measure of
bacterial susceptibility to the drug (usually the MIC).
Only the non-protein-bound fraction of an antibiotic is micro-
biologically active and can penetrate into the extravascular space [4].
Therefore, PK/PD indices are based on unbound concentrations.
For each antibiotic, diﬀerent PK/PD indices (such as AUC/MIC,
Cmax/MIC and T > MIC, Fig. 2) are tested in preclinical studies to
identify which PK/PD index is most likely to be associated with eﬃ-
cacy. PK/PD indices are diﬀerent for each antibacterial class [5]. For
example, the PK/PD index of beta-lactams is the percentage of the
dosing interval that the unbound (free) antibiotic concentration is
above the MIC (%fT > MIC) [5] and the PK/PD index of vancomycin is
fAUC0-24/MIC [6].
2.2. PK/PD targets
The PK/PD target is the minimal PK/PD index value that ensures a
high probability of successful treatment [1]. There is no unique PK/PD
target value per antibiotic. PK/PD target values vary between the
chosen endpoints such as stasis, maximal kill or resistance suppression
(for preclinical studies) and microbiological or clinical cure (for clinical
studies) [7,8].
To attain a speciﬁc PK/PD target, the exposure of the micro-
organism to the antibacterial agent needs to be adequate. This exposure
is dependent on the dose and PK properties of the drug.
2.2.1. Challenge: PK/PD target values
The optimal PK/PD target value is still not clearly deﬁned for all
antibiotics [9], in part because this depends on its clinical indication or
use. For example, for beta-lactam antibiotics, used targets vary between
40–100% fT > MIC and 50–100% fT>4xMIC [7,10,11]. Currently,
there is a trend towards the use of more conservative targets for criti-
cally ill patients than for the less critically ill. However, it may be
possible that this assumption is the consequence of variation in MIC
measurements [12]. More research in this area is clearly required. It is
also important to realize that preclinical derived PK/PD target values
diﬀer from clinical derived values in critically ill patients [7].
2.2.2. Challenge: protein binding
PK/PD indices and targets are (almost) always deﬁned as free (un-
bound) concentrations whereas many assays measure total (unbound
and protein bound) concentrations [4,13]. However, protein binding is
often highly variable and hypoalbuminemia occurs frequently in criti-
cally ill patients [14,15], which might lead to unreliable outcomes if a
free concentration is calculated using a literature value for protein
binding. In addition, protein binding can be concentration dependent
and even nonlinear [16–18].
2.2.3. Challenge: site of measurement
Most PK/PD targets are based on blood levels. However, other body
sites may be important as well, although the interpretation for these
body sites still remains uncertain [2]. If there is a good correlation
between plasma levels and body site levels this is not a major problem,
as this is just a shift in target values. If the correlation is less predictable
this may become a major issue [19]. For instance in the very obese
patients, tissue concentrations can be much lower than expected [20].
2.3. Clinical breakpoints
Information about the PK/PD target, PK characteristics, exposure,
variability and dosing regimens is needed to set clinical breakpoints.
Clinical breakpoints are MICs that deﬁne microorganisms as suscep-
tible, intermediate or resistant to speciﬁc antibiotics [21]. Clinical
breakpoints determine the antibacterial choice during empirical and
culture-driven therapy.
Fig. 1. Relationship between MIC, PK, dose and drug eﬀects.
Fig. 2. Concentration-time curve showing the pharmacokinetic parameters
Cmax (maximal concentration) and AUC (shaded area) and the PK/PD index
Time > MIC.
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3. PK analyses and simulations
PK describes the behaviour of drugs and their metabolites in the
body in terms of absorption, distribution, metabolism and elimination.
Concentration-time courses are related to the dose received and subject
characteristics. PK analysis methods can be distinguished between in-
dividual (paragraph 3.1) and population approaches (3.2), which can
be further classiﬁed as parametric, nonparametric, maximum likelihood
and Bayesian methods (Fig. 3).
Population PK models can be used to perform simulations (3.3) to
evaluate models (internal or external validation) and dosing regimens.
For the latter purpose, the probability of target attainment (PTA, 3.3.1)
can be calculated.
3.1. Individual PK methods
Individual PK methods analyse concentration-time courses per in-
dividual subject. Examples of individual PK methods are the non-
compartmental analysis and the standard-two-stage method.
Non-compartmental analysis (NCA) is the simplest individual PK
method. NCA applies no model to the data but connects the observed
individual concentrations by linear interpolation.
The standard two-stage (STS) method ﬁts the data of each in-
dividual separately into a compartmental model equation and then
combines individual parameter estimates to generate mean (popula-
tion) parameters and standard deviations [22].
Individual PK methods are relatively simple techniques and useful
to explore datasets and calculate PK measures as AUC and Cmax.
However, they don’t provide detailed information (e.g. covariates) on
variation of PK parameters in a population. Another disadvantage is
that these methods require intensive sampling. Examples of individual
PK software packages are Phoenix WinNonlin and PKSolver [23]. In
addition to NCA and/or STS methods, some of the individual PK
packages also oﬀer population PK methods.
3.2. Population PK methods
Population PK methods analyse concentration-time courses of a
population as a whole. During the modelling process, several models
with diﬀerent numbers of compartments, types of elimination and
variability are evaluated. The ﬁnal model provides mean population PK
parameters (e.g. volume of distribution, clearance) and describes
variability between subjects (inter-individual or between-subject
variability, BSV) and variability between the doses of an individual
subject (intra-individual or between-occasion variability, BOV). The
observed variability is explained by covariates (subject characteristics
as body weight, renal function or age). Residual variability (e.g. assay
variance or sampling uncertainties) is also taken in account [22,24].
Thorough model evaluation and validation is important to deliver a
robust and reliable model. Examples of model evaluation/validation
methods and techniques are objective functions based on likelihood
(e.g. AIC, Akaike Information Criterium), graphical plots, bootstrapping
to estimate parameter precision, simulation-based diagnostics (e.g.
VPC, Visual Predictive Check, or NPDE, Normalized Prediction
Distribution Error) and external validation, when the developed model
is applied to a new dataset [24,25].
Traditionally, population PK parameters were estimated by the
standard two-stage “individual” approach, which cannot describe and
explain the types of variability. More sophisticated population PK
methods involve the development of nonlinear mixed-eﬀect models.
These models are called “nonlinear” because PK equations are non-
linear. “Mixed-eﬀect” implies the description of ﬁxed eﬀects (which are
the same for each individual) and random (individual-speciﬁc) eﬀects.
Population PK modelling methods can be statistically classiﬁed as
either parametric or nonparametric. The parametric and nonparametric
classiﬁcations can both be divided into maximum likelihood or
Bayesian approaches [26,27]. The diﬀerent modelling approaches will
be brieﬂy described here.
Fig. 3. Overview of PK analysis methods. a) Non-compartmental analysis: connection of individual concentrations by linear interpolation; b) and c) Compartmental
analysis: ﬁtting of individual concentrations into a compartmental model equation (b: linear y-axis, oral administration, 1 distribution compartment. c: logarithmic y-
axis, intravenous administration, 2 distribution compartments); d) Population PK data; e) Parametric and f) Nonparametric analysis of population PK data with 2
subpopulations of slow (low Ke, elimination constant) and fast (high Ke) metabolizers. The parametric method assumes that the data are normally distributed
whereas the nonparametric method identiﬁes the 2 subpopulations. e) and f) Reprinted with permission of the Laboratory of Applied Pharmacokinetics [36].
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3.2.1. Parametric maximum likelihood methods
Parametric maximum likelihood methods assume that the popula-
tion parameter distribution is known with unknown population para-
meters [27]. These methods estimate the set of parameters that max-
imize the joint likelihood of observations. Most of the current software
packages for population PK modelling are parametric maximum like-
lihood methods (e.g. Monolix, NONMEM and Phoenix NLME). Each
package oﬀers one or more mathematic algorithms to facilitate max-
imum likelihood modelling, such as FOCE, SAEM or QRPEM [28].
3.2.2. Nonparametric maximum likelihood methods
In contrast to parametric methods, nonparametric methods make no
assumption about the shapes of the underlying parameter distributions,
which is theoretically an advantage to detect subpopulations.
Nonparametric methods use an exact likelihood function while para-
metric methods use an approximation. A drawback of nonparametric
methods is that conﬁdence intervals about parameter estimates are not
easily determined [26,27]. An example of a nonparametric maximum
likelihood method is the NPAG algorithm in the software package
Pmetrics (former MM-USCPACK / USC*PACK, previously based on the
NPEM algorithm) [29].
3.2.3. Bayesian methods
The parametric iterative two-stage Bayesian (ITB) method uses
mean parameter values and their standard deviations (obtained from a
STS method or any reasonable initial guess) as Bayesian priors.
Subsequently, individual patient data are examined to obtain Bayesian
posterior parameter values based on the maximum a posteriori prob-
ability (MAP) Bayesian procedure. The mean parameter values can
again be calculated and used as Bayesian priors to obtain new Bayesian
posterior values. This iterative process is repeated until the diﬀerence
between population and estimated values reaches a minimum value
[30,31]. Examples of software packages including the ITB method are
the KinPop module in MWPHARM [31] and the ITB algorithm in
Pmetrics, which is mainly used to estimate parameter ranges to be
passed to NPAG [29].
A nonparametric Bayesian approach is currently not available in a
software package [26].
3.2.4. Challenges: population PK approaches
It is still unknown which population PK approach (e.g. parametric
vs nonparametric) is most suitable for speciﬁc research questions. More
studies comparing both methods are warranted.
A drawback of many modelling studies is that the sample size is
usually small and that sample size calculation is lacking [7,32].
3.3. Simulations
For clinical applications, simulations using population PK models
are generally performed for two purposes: 1) model evaluation and 2)
dosing evaluation [22]. For model evaluation, concentration-time data
are simulated and compared with a subset of the original dataset (in-
ternal validation) or new data (external validation). For dosing eva-
luation, concentration-time data are simulated for several dosing regi-
mens to study the exposure and probability of target attainment (PTA,
see 3.3.1), for example in speciﬁc subpopulations such as ICU-patients
or patients with renal impairment [22,33], or during the process of
setting breakpoints [21].
Stochastic simulating from population PK models with ﬁxed-eﬀect
and random-eﬀect parameters is more complex than non-stochastic si-
mulating from simple ﬁxed-eﬀect models. The stochastic Monte Carlo
simulation (MCS) can handle random variability and is therefore the
most used simulation type for population PK models [33,34].
3.3.1. Probability of target attainment (PTA)
MCS based on population PK models can be used to calculate the
PTA of speciﬁc PK/PD targets for several dosing regimens and a range
of MICs [21,33]. Diﬀerent methods are used to present the PTA results.
One option is to plot (Fig. 4a) or tabulate the PTA of a speciﬁc PK/PD
target as a function of the MIC. Several dosing regimens can be included
in such a graph (or table). A disadvantage of this approach is that only
one PK/PD target value can be included per graph. Since the optimal
PK/PD target values are not deﬁned for all antibiotics and indications
(see 2.2.1), it may be useful to display several target values in one
graph. The latter is possible in the graph shown in Fig. 4b: the PK/PD
target (here: %fT > MIC) is plotted as a function of the MIC for a
speciﬁc dosing regimen. By including the mean (or median) of the
population and the conﬁdence interval (CI) estimations (percentiles) in
the graph, the PTA’s for several PK/PD target values can be read. The
lower boundary of a CI of 95% corresponds to a PTA of 97.5%. For
example, in Fig. 4b, the PTA for 40% fT > MIC is 97.5% for 250mg
q8h and an MIC of 0.25mg/L. EUCAST (European committee on anti-
microbial susceptibility testing) uses such graphs to determine break-
points [21].
4. Clinical applications of population PK models
Population PK models are not only used during new drug develop-
ment [2], but also have various clinical applications after the drug
becomes available to the market. From the perspective of antibiotics,
three main clinical applications can be speciﬁed: 1) dosing evaluation
of old antibiotics, 2) setting clinical breakpoints and 3) therapeutic drug
monitoring. The applications will be described in paragraphs 4.1–4.3
including the most important challenges regarding their clinical inter-
pretation (Table 1).
4.1. Dosing evaluation of old antibiotics
As described in paragraph 3.3, simulations using population PK
models can be performed to evaluate dosing regimens and subsequently
predict PTAs for diﬀerent dosing regimens and MICs. Dosing
Fig. 4. (a) PTA for various amoxicillin dosing regimens to reach the target 40%
fT > MIC for a range of MICs. Modiﬁed from [35]. (b) %fT > MIC displayed
as a function of the MIC for amoxicillin 250mg q8h. Modiﬁed from [35].
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recommendations based on such PTA simulations are increasingly
published by several research groups [37–42]. Although these pub-
lications are ﬁlling knowledge gaps for dosing in speciﬁc subgroups,
their recommendations should be carefully considered because clinical
validation is often lacking (4.4.1) and the choice of the PK/PD target
value (4.4.2) and PTA acceptance levels (4.4.3) might be questionable.
The latter does not belong to the EUCAST rationale documents for
which an exhaustive procedure is published [21].
4.1.1. Challenge: clinical validation
The most important concern is that clinical validation of the new
dosing recommendations is often lacking. It is desirable that future
clinical validation studies not only focus on target achievement, but
also relate the exposure to clinical outcomes. A recent review about the
PK/PD of gentamicin and other aminoglycosides [32] found that only 1
study prospectively evaluated model-based dosing recommendations to
see what exposure actually was achieved in clinically practice [43].
Another example of a dosing recommendation which was hardly
prospectively validated, is ciproﬂoxacin, which is illustrated in para-
graph 4.1.1.1.
4.1.1.1. Example: ciproﬂoxacin. Ciproﬂoxacin is a frequently prescribed
ﬂuoroquinolone. The pharmacodynamic target of AUC0-24/
MIC > 125 (or fAUC0-24/MIC > 100) for Pseudomonas aeruginosa is
well established in in vitro, animal and clinical studies [44–46].
According to the manufacturer, for most indications, the
recommended dosing regimen of intravenous ciproﬂoxacin is 400mg
twice or three times daily in patients with normal renal function
[47,48], which implies that the dosing frequency can be chosen by
the prescribing physician. However, an increasing number of
simulation studies using population PK models show that a dosing
regimen of 1200mg/day is necessary to attain the pharmacodynamic
target of AUC0-24/MIC > 125 (or 100 for unbound drug) for Gram-
negative pathogens with an MIC≥ 0.5 mg/L [46,49–52].
A major drawback of these studies is that the dosing re-
commendations of 400mg q8h for MICs ≥ 0.5 mg/L were based on
simulations and not prospectively validated. The majority of the study
population received a daily dose of maximally 800mg/day.
Despite the fact that these studies resulted in the same conclusion,
the study designs were remarkable diﬀerent. Some study populations
were only ICU patients [49,51] while other study populations also in-
cluded general ward patients [46,50,52]. Some studies reduced the
dose in patients with impaired renal function, each using a diﬀerent
dosing algorithm [46,50,52], while in other studies dose reduction was
not applied [49,51]. Translation of these recommendations to clinical
practice is therefore diﬃcult. Even the EMA and FDA provide diﬀerent
dosing recommendations for ciproﬂoxacin in patients with impaired
renal function [47,53].
4.1.2. Challenge: PK/PD targets
As discussed in 2.2.1, the PK/PD targets for some antibiotics and
populations are still unclear [3]. Some authors use two or more targets
and give diﬀerent dosing recommendations depending on the target
[37]. The previously mentioned review about gentamicin [32] showed
that the chosen targets in 7 simulation studies in adults varied between
Cmax ≥ 8mg/L, Cmax> 10mg/L, Cmax= 22mg/L, Cmax/MIC > 8,
Cmax/MIC≥ 10, AUC24 70–120 mg*h/L and AUC48>140 mg*h/L.
4.1.3. Challenge: PTA interpretation
Another problem is that PTA interpretation is not standardized.
Used PTA acceptance levels vary between 90–100% and are sometimes
not even mentioned. However, it is important to realize that a PTA of
90% means that 10% of the patients do not attain the target for a
speciﬁc MIC, which implicates that the probability for successful
treatment is diminished. For new antimicrobials, the EMA indicates a
PTA of 90% for dose selection [2].
The chosen MICs for the dosing recommendations should always be
weighed against the internationally published MIC clinical breakpoints.
EUCAST uses the MIC values based on PTA’s of 97.5% and 99% for
setting breakpoints [21].
4.2. Setting clinical breakpoints
The EUCAST provides species-related and PK/PD (non-species re-
lated) clinical breakpoints. The EUCAST procedure for setting PK/PD
breakpoints includes MCS using population PK models to estimate ex-
posure of an antimicrobial agent in the target patient population for
commonly used dosing regimens [21]. Following the simulations, the
PTA is determined for diﬀerent PK/PD targets. Subsequently, the PK/
PD target is plotted as a function of the MIC for the mean of the po-
pulation and 95% and 99% CI estimates (corresponding to 97.5% and
99.5% PTA). EUCAST uses the MIC values resulting from both PTAs to
determine a PK/PD breakpoint [21].
4.3. Therapeutic drug monitoring (TDM)
Therapeutic drug monitoring is the measurement of drug con-
centrations to optimize dosing regimens for individual patients with the
objective to maximize eﬃcacy and minimize toxicity [54]. Criteria for a
drug to be appropriate for TDM are: large between-subject variability,
small between-occasion variability, deﬁned concentration-eﬀect re-
lationship, small therapeutic range, available analysis method and no
clearly deﬁned clinical parameter that allows dose adjustments (e.g.
glucose or INR levels) [55].
4.3.1. TDM approaches
TDM can be applied by evaluating whether the drug concentrations
are in the therapeutic range, but in case of deviating concentrations, or
when the therapeutic target is not just a concentration but e.g. an AUC,
it is diﬃcult to provide a dosing recommendation manually. A more
robust approach to individualize dosing by TDM is the maximum a
posteriori probability (MAP) Bayesian ﬁtting procedure [30] (see
3.2.3), which is implemented in various TDM software programs [7,56]
(see 4.3.2). The library of these TDM software tools include population
parameters, SD’s and covariates based on population PK models.
4.3.2. TDM software programs
Several TDM computer tools are available. In 2012, a review of 12
software tools was published [56]; they diﬀer in the number of drugs
oﬀered in the library (from 2 to 180). Eight of these programs provide
the option to add new drug models. Other diﬀerences are the
Table 1
Challenges per clinical application of population PK models. The degree of
importance is scored with ++ (highly important), + (important), - (not ap-
plicable). The most important challenges are further clariﬁed in the text (the
respective paragraph is indicated between brackets).
Challenges Clinical applications of population PK models
1. Dosing
evaluation of old
antibiotics
2. Setting
clinical
breakpoints
3. Therapeutic
drug monitoring
PK/PD targets ++ (2.2.1,
4.1.2)
++ (2.2.1) ++ (2.2.1)
Protein binding + (2.2.2) ++ (2.2.2) ++ (2.2.2)
Site of measurement + (2.2.3) + (2.2.3) + (2.2.3)
Clinical validation ++ (4.1.1) + ++ (4.3.4)
PTA interpretation ++ (4.1.3) ++ –
Population PK model
selection
+ + ++ (4.3.5)
Assay availability + + ++ (4.3.6)
MIC accuracy and
variation
+ + ++ (4.3.7)
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availability of MAP Bayesian dosage adaptation (10/12 tools, see 3.2.3
for background information) and the proposal of a priori dosage regi-
mens based on certain covariates (9/12 tools). The authors of the re-
view recommend that most TDM software tools can be improved, more
speciﬁcally the interface, user friendliness, data storage capability and
report generation.
4.3.3. TDM in clinical practice
TDM is applied to many antibiotic classes. For aminoglycosides (e.g.
gentamicin, tobramycin and amikacin) and glycopeptides (e.g. vanco-
mycin and teicoplanin), TDM has become standard clinical practice to
balance eﬃcacy and toxicity [57,58]. For other groups, such as beta-
lactams and ﬂuoroquinolones, TDM is not yet commonly employed
[57,58]. The most important reasons that TDM is not commonly used
for all antibiotic classes are unclear therapeutic targets (see 2.2.1), the
lack of clinical outcome studies (4.3.4) and the unavailability of an
assay in the hospital (4.3.6) [57–63].
4.3.4. Challenge: clinical validation
Despite the fact that TDM is used extensively in clinical practice,
there is a paucity of prospective studies on the inﬂuence of TDM on
clinical outcomes [57,58,61–63]. Also for antibiotics which are already
in TDM programs, prospective studies are sparse [54].
Examples of prospective studies are highlighted in the next para-
graph 4.3.4.1.
4.3.4.1. Examples: aminoglycosides, vancomycin, ﬂuoroquinolones, beta-
lactams. Two prospective controlled studies about aminoglycoside
TDM using Bayesian software showed that TDM signiﬁcantly reduced
nephrotoxicity, hospitalization and costs [64,65]. However, these two
studies were performed before the introduction of extended-interval
dosing of aminoglycosides and might not reﬂect the current practice.
For vancomycin, two prospective controlled studies showed that
TDM signiﬁcantly reduced nephrotoxicity [66,67].
A prospective controlled study including amikacin, ciproﬂoxacin,
levoﬂoxacin, ceftazidime and cefotaxime showed that TDM improved
the probability of a good clinical outcome and pathogen eradication
[68]. In this study, Bayesian software was used only for amikacin and
the two ﬂuoroquinolones, but not for the two beta-lactams [68].
Another prospective beta-lactam TDM study didn’t use Bayesian
software to adjust dosing, but manually adjusted the frequency or in-
fusion time [69]. Dosing was adjusted if the trough or steady state
unbound concentration was below 4-5x MIC or above 10x MIC, which
happened in 74.2% of the patients [69]. A main drawback of this study
was the calculation of free concentrations using measured total con-
centrations and literature values for protein binding, while protein
binding is often highly variable in critically ill patients [14]. Another
limitation was the unavailability of MICs for a major part of the study
population. By using ECOFFs (EUCAST epidemiological cut-oﬀ value)
when a pathogen was isolated but no MIC available, or a MIC based on
local epidemiology information of a potential pathogen (when no pa-
thogen was isolated), a worst case scenario was applied and dosing
adjustments might have been unnecessary [12]. In 2018, a prospective
Dutch study evaluating a Bayesian TDM software program of beta-lac-
tams will begin (the DIABOLO study, https://www.
clinicaltrialsregister.eu/ctr-search/trial/2017-004677-14/NL).
4.3.5. Challenge: population PK model selection
An important aspect of reliable TDM programs is the choice of a
population PK model which must be suitable for the patient population
for which TDM is performed.
Neef and colleagues presented a case of vancomycin MAP Bayesian
adjustment where 4 diﬀerent population PK models resulted in 4
strikingly diﬀerent dosing schemes recommendations [70], see the ex-
ample in 4.3.5.1 below.
Another study evaluated diﬀerent population PK models for ami-
kacin and also showed signiﬁcant diﬀerences in model performance
(results not shown here) [71].
4.3.5.1. Example: vancomycin. This case [70] describes a 3-week-old
neonate (3.6 kg, 50 cm, serum creatinine 25 μmol/L) receiving
vancomycin 70mg every 12 h with an infusion duration of 2 h. Two
levels were drawn before and after the third dose. Fig. 5 shows the TDM
performance of 4 models (presented in Table 2) for 4 tested dosing
Fig. 5. TDM performance of 4 population models A–D (details displayed in Table 2) for 4 tested dosing regimens for each model: 1) 50mg/24 h continuous infusion,
2) 100mg/24 h continuous infusion, 3) 25mg/12 h, 4) 10mg/24 h. Reprinted with permission from Therapeutic Drug Monitoring [70].
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regimens. It is clear that model D has the worst ﬁt of the measured
levels. The other models have better ﬁts, but model A predicts very high
levels, probably due to absence of clearance in the model parameters.
The conclusion of the authors is that model B best ﬁt the data.
4.3.6. Challenge: assay availability
Obviously, the availability of an assay is a limiting condition for
TDM. However, the availability of assays diﬀers per antibiotic and also
per hospital. Most hospitals have assays for aminoglycosides and van-
comycin [70], but assays for beta-lactams and ﬂuoroquinolones are less
common [10,13]. Possible reasons preventing institutions to provide
TDM could be the absence of a prospective clinical outcome study or
the requirement of a chromatographic method instead of an im-
munoassay [10].
4.3.7. Challenge: MIC accuracy and variation
For dose adjustment of antibiotics based on TDM, both the measure
of the concentration of the drug itself and the MIC of the pathogen
responsible for the infection are necessary. However, most institutions
use a single MIC determination which is inappropriate and can poten-
tially cause underdosing of patients [12]. The accuracy and variation of
MIC measurements must be carefully considered during this process
[12].
5. Perspectives
The present review intended to provide background information on
the current clinical applications of population PK modelling of anti-
biotics. There is an abundance of published population PK models
which are used to evaluate dosing regimens, implemented in TDM
software programs or used to set clinical breakpoints. These applica-
tions can be helpful to optimize the eﬃcacy-toxicity balance of anti-
biotics, but have some limitations and knowledge gaps for which future
research is needed.
5.1. PK/PD targets
More clarity about the optimal PK/PD target value of some anti-
biotics for speciﬁc clinical indications is required. Without a clear PK/
PD target value, dosing recommendations from modelling and simula-
tion studies are diﬃcult to interpret and individualised dosing using
TDM is hard to implement.
5.2. Assays
Obviously, an assay to measure antibiotic concentrations is essential
to provide input for population PK models and to use them in clinical
practise. It is important to measure unbound concentrations of anti-
biotics with a large variability in protein binding. Currently, assays for
plasma concentrations are suﬃcient for clinical use because most cur-
rent PK/PD target values are based on the concentrations in the central
compartment, although the concentration at the infection site might
also be important. Research on this topic is ongoing.
5.3. Population PK modelling and simulation
For reliable individual dosing recommendations in TDM programs
as well as general dosing recommendations for speciﬁc patient groups,
the choice of a population PK model suitable for that population is
crucial. The used PTA acceptance levels in published dosing re-
commendations should be carefully considered.
PBPK (Physiologically Based PK) modelling methods [63] and
joined clinical PK and PD modelling methods [61] are newer modelling
methods which need to be further explored.
5.4. Clinical validation
It is imperative that the beneﬁcial eﬀects of dosing individualisation
using TDM software be more prospectively studied. MIC accuracy and
variation should be carefully considered during this process [12].
5.5. Interpretation of population PK modelling studies
Little knowledge of PK/PD and modelling prevents a good under-
standing of dosing recommendations resulting from modelling and si-
mulation studies, clinical breakpoints and TDM. Therefore, good edu-
cation on these topics is essential to improve antibiotic dosing in
clinical practise.
6. Conclusions
Population PK models are extensively used in clinical practice to
optimize antibiotic dosing. However, more clarity about PK/PD targets
values, more clinical evaluation studies of model-based dosing re-
commendations and more clinical outcome studies of TDM are re-
quired.
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